News

The large amount of enthusiasm behind the potential applications of plasma cell-free DNA (cfDNA) analysis appears to have outpaced our...

New research1 presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) from 4th-8th November 2017 in Glasgow, Scotland...

New research1 presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting from 4th-8th November 2017 in Glasgow,...

The progression-free survival (PFS) of patients with heavily pre-treated rare or refractory cancer usually declines with every new line of...

The National Institute for Health and Care Excellence (NICE) has released a medical technology innovation briefing on Caris Molecular Intelligence...

An original complaint against Foundation Medicine Inc. has recently been filed by Guardant Health Inc. Guardant seeks to recover damages and...

In April 2014, OncoDNA, a clinical NGS provider affiliated with the Institute of Pathology and Genetics in Gosselies, Belgium, announced...

Results of a molecular profiling analysis to identify the frequency of Homologous Recombination Deficiencies (HRD) from approximately 53,000 tumours have...

Caris Life Sciences® has announced a collaboration with the National Cancer Institute (NCI) for the NCI-Molecular Analysis for Therapy Choice...

The primary objective of this study was to estimate the efficacy of the immunotherapy drug pembrolizumab in patients with MSI-High...

Caris is one of the first laboratories to have a test report optimised for ASCO’s Targeted Agent and Profiling Utilization...